Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study.
Authors
Kennelly, S PAbdullah, L
Paris, D
Parish, J
Mathura, V
Mullan, M
Crawford, F
Lawlor, B A
Kenny, R A
Affiliation
St. James Hospital, Dublin, Ireland. skennelly1976@hotmail.comIssue Date
2012-02-01T10:45:58ZMeSH
AgedAged, 80 and over
Alzheimer Disease/*drug therapy
Antihypertensive Agents/*adverse effects
Blood Pressure/*drug effects
Female
Humans
Male
Middle Aged
Nifedipine/adverse effects/*analogs & derivatives
Metadata
Show full item recordCitation
Int J Geriatr Psychiatry. 2011 Oct;26(10):1038-45. doi: 10.1002/gps.2638. Epub, 2010 Oct 29.Journal
International journal of geriatric psychiatryDOI
10.1002/gps.2638PubMed ID
21905098Abstract
BACKGROUND: Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer's disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypotension (OH) in this population, who may be more likely to suffer from symptoms associated with the further exaggeration of a drop in BP. OBJECTIVE: The aim of this study was to investigate the safety and tolerability of nilvadipine in AD patients. METHODS: AD patients in the intervention group (n = 56) received nilvadipine 8 mg daily over 6-weeks, compared to the control group (n = 30) who received no intervention. Differences in systolic (SBP) and diastolic (DBP) blood pressure, before and after intervention, was assessed using automated sphygmomanometer readings and ambulatory BP monitors (ABP), and change in OH using a finometer. Reporting of adverse events was monitored throughout the study. RESULTS: There was a significant reduction in the SBP of treated patients compared to non-treated patients but no significant change in DBP. Individuals with higher initial blood pressure (BP) had greater reduction in BP but individuals with normal BP did not experience much change in their BP. While OH was present in 84% of the patients, there was no further drop in BP recorded on active stand studies. There were no significant differences in adverse event reporting between groups. CONCLUSION: Nilvadipine was well tolerated by patients with AD. This study supports further investigation of its efficacy as a potential treatment for AD.Language
engISSN
1099-1166 (Electronic)0885-6230 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1002/gps.2638
Scopus Count
Collections
Related articles
- Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial.
- Authors: Kennelly S, Abdullah L, Kenny RA, Mathura V, Luis CA, Mouzon B, Crawford F, Mullan M, Lawlor B
- Issue date: 2012 Apr
- Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial.
- Authors: Leonetti G, Italian Study Group on Nilvadipine in Mild to Moderate Hypertension
- Issue date: 2005 Jun
- Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
- Authors: Germino FW
- Issue date: 2009 Sep
- Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
- Authors: de la Sierra A, Gil-Extremera B, Calvo C, Campo C, García-Puig J, Márquez E, Oliván J, Roca Cusachs A, Sanz de Castro S, Pontes C, Delgadillo J
- Issue date: 2004 Mar
- Comparisons of once-daily nilvadipine with enalapril and diuretic in patients with essential hypertension.
- Authors: Fritschka E
- Issue date: 1992